Citi Downgrades Relypsa, Inc. (RLYP) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cantor Fitzgerald Downgrades Relypsa, Inc. (RLYP) to Hold
July 26, 2016 7:38 AM EDTCantor Fitzgerald downgraded Relypsa, Inc. (NASDAQ: RLYP) from Buy to Hold with a price target of $32.00 (from $41.00).
For an analyst ratings summary and ratings history on Relypsa, Inc. click here. For more ratings news on Relypsa, Inc. click here.
Shares of Relypsa, Inc. closed at $31.97 yesterday.
... MoreGalenica to Acquire Relypsa (RLYP) for $32/Share
July 21, 2016 5:42 AM EDTGalenica Group and Relypsa, Inc. (Nasdaq: RLYP) announced that the companies have entered into a definitive agreement under which Galenica will acquire Relypsa. This transaction further strengthens Galenicas Business unit, Vifor Pharma, as the company will gain full global rights to the potassium binder Veltassa (patiromer) for oral suspension and enhance its growing position as a global specialty pharmaceutical company. Under the terms of the merger agreement, Galenica will pay $32 per share in cash, or a total of approximately $1.53 billion. Through this acquisition, Vifor Pharma will gain a fully-integrated commercial organization in the United... More
